enVVeno Medical Corp
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Selling, general & administrative | $10.9M | $11.6M | $11.7M | $15.0M | $11.2M |
| Research and development | $10.0M | $12.2M | $13.6M | $9.9M | $5.7M |
| Operating income | -$20.9M | -$23.8M | -$25.2M | -$24.9M | -$16.9M |
| Pretax income | -$19.5M | -$21.8M | — | — | — |
| Net income | -$19.5M | -$21.8M | -$23.5M | -$24.7M | -$16.5M |
| Balance Sheet | |||||
| Cash and equivalents | $3.1M | $1.8M | $3.6M | $4.6M | $54.7M |
| Current assets | $28.8M | $43.7M | $46.9M | $39.4M | $55.0M |
| Total assets | $29.6M | $45.0M | $48.6M | $41.7M | $57.7M |
| Current liabilities | $2.1M | $2.1M | $1.4M | $1.5M | $1.6M |
| Total liabilities | $2.4M | $2.8M | $2.4M | $2.9M | $3.3M |
| Stockholders' equity | $27.1M | $42.2M | $46.2M | $38.7M | $54.4M |
| Cash Flow Statement | |||||
| Cash from operations | -$15.6M | -$16.8M | -$18.9M | -$15.6M | -$11.8M |
| Depreciation and amortization | $100,000 | $200,000 | $200,000 | $200,000 | $100,000 |
| Stock-based compensation | $3.4M | $4.1M | $5.2M | $9.0M | $6.0M |
| Capital expenditure | $5,000 | $37,000 | $33,000 | $115,000 | $368,000 |
| Free cash flow | -$15.6M | -$16.9M | -$18.9M | -$15.7M | -$12.2M |
Shares outstanding 667.7K · Free float 96.1%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.